⚕️ Bristol-Myers Squibb Hearts MyoKardia!

What you need to know before the US markets open 🇺🇸

Hey Global Investor, here’s what you need to know before the US markets open.

Market Snapshot 📈

S&P 500 (Monday Close) 3,408.63 +60.19 (1.80%)

NASDAQ (Monday Close) 11,332.48 +257.47 (2.32%)

FTSE 100 (5 PM IST) 5,951.95 +9.01 (0.15%)

NIFTY 50 (Today’s Close) 11,662.40 +159.05 (1.38%)

USDINR (5 PM IST) 73.45 (1 Year +2.93%)

⚕️Bristol-Myers Squibb Hearts MyoKardia!

In an all-cash deal, Bristol-Myers Squibb is buying biotech company MyoKardia in order to acquire its product pipeline.

What Happened? Hypertrophic Cardiomyopathy (HCM for short) might be a mouthful to pronounce. But in the case of executives at MyoKardia, it meant a $13.1B check and a validation of its strategy. The company is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases.

HCM is a condition in which the heart muscle becomes abnormally thick and makes it hard for the heart to pump blood. This can cause arrhythmia (irregular heartbeats) which can be life threatening. It is the most common genetic heart disease affecting 1 in every 500 people.

Enter MyoKardia, founded in 2012 and based in Brisbane, California. The company successfully completed Phase 3 trials of its investigational drug Mavacamten and met all of the requirements. The drug will be submitted to the FDA for approval in the first quarter of 2021 for treating HCM. In the company’s pipeline are a couple of other products for treating heart failure which are currently in earlier-phase trials. Mavacamten along with its sister products is expected to produce peak annual sales in the $4-5B range.

Bristol swooped in with an offer that the Board of Directors at MyoKardia could not overlook. The transaction, which values MyoKardia at $225 per share, was unanimously approved by the Boards of the two companies. The acquisition of MyoKardia gives a further boost to Bristol’s product pipeline, and adds to the next-generation anti-clotting treatment it’s currently working on. Expected to close in Q4 2020, this acquisition will be accretive to Bristol beginning in 2023.

Market reaction: In response to this announcement, the stock of MyoKardia (MYOK) soared $80.74 or 57.84% to $220.34. Bristol’s stock rose 0.82% to $59.20.

Company Snapshot 📈

BMY $59.20 +0.51 (0.87%)

MYOK $220.34 +80.74 (57.84%)

Newsworthy 📰

Alibaba Buys: Alibaba To Pick Up Nearly 10% Stake In Dufry With $763M Investment (BABA -0.01%)
Gold Shines: Gold prices end at 2-week high on dollar weakness, fresh stimulus talk
China Rebounds: China’s Economic Recovery Helps Drive Its Stocks Higher

Later Today 🕒

6.00 PM IST: Trade Deficit
7.30 PM IST: Job openings

“Fun Fact of The Day” 🌞

Ketchup was sold as medicine in the 1830s

Disclaimer: The content of this article has been created and published by Winvesta India Technologies Pvt. Ltd., in order to ease the reader’s understanding of the subject matter. The information and/or content (collectively “Information”) provided herein is general information sourced through various news reports and does not constitute a research report or a research analysis. The Information is not intended to offer advice, target or solicit any particular customer or group of customers to buy or sell securities.

Winvesta does not render any research or advisory services and provides a more detailed description of its services on its website and mobile application along with the terms and conditions published therein from time to time. While reasonable care has been exercised to ensure that the Information is adequate and reliable, no representation is made by Winvesta as to its accuracy or completeness and Winvesta, its affiliates, subsidiaries and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this Information. Neither Winvesta nor any of its affiliates are acting as an investment adviser, research analyst or in any other fiduciary capacity. Accordingly, reader’s are expected to undertake their own due diligence in consultation with their own advisors and are advised not to solely rely on the Information. Any such reliance shall be at the reader’s own risk.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing.